加拿大ImmunoVaccine Technologies Inc. (IVT) www.immunovaccine.com
ImmunoVaccine Technologies Inc. (哈立法克斯，Halifax)是發(fā)展疫苗的公司，宣布派任曾任國會議員的Michael Kirby先生接替Dr. Warrick Kimmins醫(yī)生，擔當公司新董事長。Dr. Warrick Kimmins醫(yī)生在他的任期內(nèi)對公司提供了絕佳領(lǐng)導風范，也曾主導Dalhousie University大學上游創(chuàng)新科技移轉(zhuǎn)，成為IVT公司的科技平臺。
ImmunoVaccine Technologies Inc. (IVT) is a pre-clinical stage private biotechnology company developing therapeutic cancer and prophylactic infectious disease vaccines for human health. IVT is commercializing breakthrough vaccines developed through the combination of the VacciMax® platform, a vaccine delivery and enhancement system and a large selection of validated vaccine antigens. The combination of the right antigens and strong novel delivery will give IVT’s pipeline a distinct competitive advantage and will position IVT as a key player in development of premium vaccine products.
 
The VacciMax® platform is able to stimulate an earlier, more powerful, long lasting antibody and cellular immune response. IVT is also able to reduce the number of doses required for protection against infectious diseases like influenza. IVT has completed the scale-up and manufacturing method development for the VacciMax® platform. The company is planning to begin a Phase 1 clinical trial for a therapeutic cancer vaccine in 2009.